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Abstract 
Purpose: To compare the effectiveness and safety of intravenous cisplatin (DDP) and 5-fluorouracil (5-
FU) alone or in combination with continuous hyperthermic peritoneal perfusion (CHPP) for the treatment 
of malignant ascites. 
Methods: In the study, 124 patients with tumour-induced malignant ascites were assign to test and 
control groups according to the sequence of their hospital visits. Patients in the test group were treated 
with intravenous DDP and 5-FU combined with CHPP, whereas patients in the control group were only 
treated with DDP and 5-FU. The treatments in both groups lasted for 4 weeks. Thereafter, treatment 
efficacy, remission of abdominal distension, ascites, Karnofsky Performance Scale (KPS) score, and 
incidence of adverse reactions were compared between the two groups.  
Results: The overall response rates of the test and control groups were 85.50 (53/62) and 35.50 % 
(22/62), respectively, and the difference was significant (p < 0.05). Patients in the test group showed 
significant reduction in abdominal distension and markedly reduced ascites compared to the controls. 
The improvement in KPS score was superior in the test group (p < 0.05). No treatment-associated 
complications, such as intestinal adhesions or obstruction and grade III or IV toxic and side reactions, 
were found in either group. The incidence of adverse reactions was lower in the test group than in the 
controls. 
Conclusion: Chemotherapy in combination with CHPP is safe and effective for patients with advanced 
malignant tumours and ascites should be promoted clinically. 
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Malignant ascites refers to abnormally increased 
liquid in the abdomen induced by diffuse lesions 
caused by systemic or abdominal malignancies 
[1,2]. When there is little ascites, subjective 
symptoms are not obvious, whereas more 
ascites can induce symptoms such as abdominal 
distension, stomach ache, shortness of breath, 
gastrointestinal dysfunction, and even intestinal 
obstruction, which can severely affect the 
patient’s quality of life [3,4]. Although the survival 
of patients with malignant tumours is low, 
successful treatment can improve the prognosis 
of patients with malignant ascites. 
 
There are many treatments for malignant ascites; 
however, each has limitations. Surgery and 
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radiotherapy cannot effectively eradicate large 
lesions, and intravenous chemotherapy is 
ineffective when using drugs that have low 
concentrations in the abdominal cavity [5,6]. 
Some researchers have developed a new 
treatment, namely continuous hyperthermic 
peritoneal perfusion (CHPP), which is based on 
the different tolerance of tumour and normal cells 
to temperature and the synergistic effects of 
thermo-chemotherapy [7]. CHPP can prevent 
tumour recurrence by killing free tumour cells in 
the abdominal cavity and small metastases. To 
investigate the safety and effectiveness of 
CHPP, this retrospective study analysed 124 
cases of malignant ascites seen at Binzhou 
People’s Hospital, Shandong, China, and 
compared the safety and effectiveness of CHPP 







The study enrolled 124 patients who had 
malignant tumour-induced malignant ascites and 
were admitted to Binzhou People’s Hospital from 
December 2013 to December 2015. They were 
randomly divided into test and control groups 
according to the admission time. The test group 
comprised 30 males and 32 females, with a 
median age of 60 (range 44 - 76) years; there 
were 25 cases of ovarian cancer, 16 cases of 
gastric carcinoma, 12 cases of liver cancer, 6 
cases of oesophageal carcinoma, and 3 cases of 
intestinal cancer. The control group comprised 
27 males and 35 females, , with a median age of 
58 (range 42 - 71) years; there were 22 cases of 
gastric carcinoma, 20 cases of ovarian cancer, 7 
cases of intestinal cancer, and 6 cases of 
oesophageal carcinoma. The differences in sex, 
age, and disease between the two groups were 
not significant (p > 0.05). The study was 
approved by the Medical Ethics Committee of 
Binzhou People’s Hospital (approval no. 
BZPH201602018LC), and the experiment 
followed the guidelines of the 
Declaration of Helsinki [8]. 
 




The study included patients who were at least 18 
years old; had pathologically or cytologically 
confirmed malignant tumours and malignant 
ascites; had indications for systemic 
chemotherapy; accepted the first-line 
chemotherapy regimen; were diagnosed with 
uncoated ascites (≥ 5 cm) by B ultrasound or 
computed tomography; had a Karnofsky 
performance scale (KPS) score of at least 60; 
had predicted survival exceeding 4 weeks; had 
no severe cardiac, hepatic, or pulmonary 
dysfunction; had no contraindications to 
chemotherapy; agreed to the release of relevant 
treatment data; and had been informed of the 




Patients were excluded if they had a KPS score 
less than 60 points; could not tolerate 
chemotherapy; had undergone chemotherapy or 
specific treatment in the 4 weeks before this 
study; had poor bone marrow function or severe 
anaemia; had white blood cell and platelet counts 
below the normal levels; were suffering from 
intestinal obstruction, peritoneal adhesions, or 
intra-abdominal infection; had ascites induced by 
liver cirrhosis or other diseases; failed to follow 
the treatment plans formulated by doctors; or 
could not control their own behaviours and 
language because of diseases such as mental 






Patients in the control group were treated with 
systemic intravenous chemotherapy comprising 
cisplatin (CDDP; Jinzhou Jiutai Pharmaceutical 
Co., Ltd., China; Batch no. 21020212) at a dose 
of 100 mg/m2, once every 3 weeks and 5-
fluorouracil (5-FU; Shanghai Xudong 
Pharmaceutical Co. Ltd, China, Batch no. 
H31020593) 500 mg each time, once a week, 
with a 2 - week interval after every 4 - week 
cycle. In addition, potassium chloride, mannitol, 
and furosemide were used for hydration and 
dieresis; the urine volume was controlled at 2000 
mL/d. Abdominal puncture and tapping were 
performed under ultrasound guidance once every 
2 days. The tapping rate was kept between 1500 
and 2000 mL. This treatment plan was used 




Patients in the test group were treated with 
CHPP. With the patient in a supine position 
supported by a pillow, the left and right upper 
and lower abdomen were examined by B 
ultrasound. Sites with sufficient ascites and no 
adhesions between the abdominal wall and 
organs and tissues in the abdominal cavity were 
selected for puncture. The punctures were kept 
away from any original abdominal wounds. The 
puncture sites were disinfected. After local 
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anaesthesia using 0.5 % lidocaine, a 1 cm long 
incision was made at each puncture site and a 1 
cm diameter trocar was inserted into the 
abdominal cavity. Then perfusion catheters were 
inserted into the left and right upper abdomen, 
and outflow catheters were inserted into the left 
and right lower abdomen; the insertion lengths 
were about 80 cm. Next, 1500 mg 5-FU and 100 
mg DDP were added to 2500 - 4500 mL normal 
saline. The amount of normal saline was 
adjusted to the volume of ascites such that the 
perfusion liquid could be pumped through the 
closed pipeline system. The perfusion was 
controlled at a speed of 500 mL/min at 41.5 °C ± 
0.2 °C, for 60 - 90 min. To relieve abdominal pain 
and increase the sensitivity to thermotherapy, 
100 mg of 2 % lidocaine was added. To prevent 
gastrointestinal side effects, an anti-emetic, 
dexamethasone, and Vitamin B6 were 
administered 30 min before perfusion. To relieve 
abdominal distension, some of the perfusion 
liquid was removed after each perfusion. The 
patients were given diuretics, intravenous 
infusions, and supportive treatment such as 
supplemental albumin and plasma. This 







According to the World Health Organization 
Response Evaluation Criteria in Solid Tumours 
[9], complete disappearance of ascites for more 
than 4 weeks is considered complete remission 
(CR), a one-half or greater reduction in the 
ascites for more than 4 weeks is considered 
partial remission (PR), a reduction in the ascites 
of less than one-half or no obvious changes is 
considered no remission (NR), and increased 
ascites or aggravated symptoms are deemed 
progressive disease (PD). The overall response 
rate was calculated as: 
 
R = (a + b)/N * 100% ………………. (1) 
 
where R is the overall response rate, a is cases 
of CR, b is cases of PR, and N is the total 
number of cases. The abdominal distention was 
scored before treatment and 1 week after 
treatment as follows: severe abdominal 
distension that affected breathing, 3 points; 
severe abdominal distension that had no 
influence on breathing, 2 points; abdominal 
distension that had no influence on life, 1 point; 
and no abdominal distension, 0 points. The depth 
of fluid sonolucent areas was examined by 
abdominal B ultrasound before and 1 week after 
treatment and compared. 
KPS score 
 
The KPS scores before treatment and 4 weeks 
after treatment were compared between the two 
groups. An increase in 10 or more points 
compared to the score before treatment indicated 
improved quality of life; an increase or decrease 
in no more than 10 points was deemed stable 
quality of life; and a decrease in more than 10 




The National Cancer Institute Common Toxicity 
Criteria [10] were used to evaluate the state of 
different systems after treatment, and to 
determine the toxic and side effects on different 
systems. Signs of intestinal obstruction, intestinal 
adhesions, gastrointestinal symptoms (nausea, 
emesis, abdominal distension, and stomach 
ache), fever, lack of strength, diaphoresis, 
intestinal paralysis, white blood cell reduction, 




The data were analysed statistically using SPSS 
ver. 20.0. Enumeration data are expressed as 
the rate. The results are reported as mean ± 
standard deviation (SD). Groups were compared 
to the chi-square test or t-test as appropriate. 
Differences were considered statistically 




Curative effects seen in both groups 
 
The overall response rate of the test group was 
85.50 %, including 37 cases of CR, 16 cases of 
PR, 6 cases of NR, and 3 cases of PD. The 
overall response rate of the control group was 
35.50 %, including 13 cases of CR, 9 cases of 
PR, 26 cases of NR, and 14 cases of PD. The 
overall response rate of the test group was 
higher than that of the control group (p < 0.05). 
 
Improvement in abdominal distension and 
ascites changes in both groups 
 
Before treatment, the difference in the abdominal 
distension scores of the two groups was not 
significant. After treatment, the abdominal 
distension scores improved in both groups, but 
the improvement in the test group was superior 
to that in the control group (p < 0.05; Table 1). 
Before treatment, the depth of ascites was 
similar in both groups; after treatment, the depth 
of ascites decreased in both groups, and the 
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Table 1: Comparison of the abdominal distension scores and ascites in the two 
groups before and after treatment (mean ± SD) 
 
Variable Test group Control group 
Abdominal distention score 
(points) 
Before 2.42±0.71 2.53±0.79 








After 1.87±2.49*# 4.91±2.57# 
    Notes: *P < 0.05 compared to the control group; #p < 0.05 compared to before treatment 
 
 
Figure 1: KPS scores 
 
Table 2: Incidence of adverse reactions {N (%)} 
 
Variable Test group Control group 
Nausea and vomiting 52 (83.9) 41 (66.1) 
Fever, lack of strength and diaphoresis 30 (48.4) 22 (35.5) 
Abdominal distension and pain 9 (14.5) 5 (8.1) 
Intestinal paralysis and obstruction 0 (0.0) 0 (0.0) 
Decreased white blood cells 43 (69.4)* 62 (100.0)* 
Myelosuppression 18 (29.0)* 44 (71.0)* 
Note: *P < 0.05 compared to the control group 
 
decrease in the test group was much larger than 
that in the control group (p < 0.05; Table 2). 
 
Changes in KPS score  
 
A total of 8 cases in the test group and 3 cases in 
the controls had improved scores, and 25 cases 
in the test group and 20 cases in the controls had 
stable scores. The improvement rate (number of 
cases with improved scores/total number of 
cases + number of cases with stable scores/total 
number of cases) of the test group and the 
control groups was 53.20 % and 37.10 %, 
respectively (p < 0.05; Figure 1). 
 
Incidence of adverse reactions  
 
No patient stopped treatment because of 
adverse reactions during treatment. After 
treatment, the vital signs of all patients were 
stable, and biochemical indices of hepatic and 
renal function showed no obvious changes. Most 
of the chemotherapy-associated toxic and side 
effects such as haematological toxicity, abnormal 
liver function, urinary system toxicity, and allergy 
were grade 0. The reduction in white blood cells 
and myelosuppression significantly differed in the 




Malignant ascites is the abnormal accumulation 
of ascites induced by a malignant tumour, which 
usually indicates the terminal stage of disease. 
Important aspects of the treatment of terminal 
tumours are how to reduce the uncomfortable 
symptoms induced by ascites and improve the 
patient’s quality of life [11,12]. 
 
Current treatments for malignant ascites include 
symptomatic and supportive treatment, diuresis, 
puncture and drainage, intra-abdominal drug 
perfusion, immunotherapy, and anti-
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angiogenesis treatment. However, these 
treatments all have limitations and the overall 
outcomes are poor. Recently, thermal therapy 
has been used extensively [13]. Thermal therapy 
kills tumour cells by heating tissues to a 
temperature that will kill tumours cells without 
damaging normal cells; it is called a green 
therapy because it is a physical method [14,15]. 
 
CHPP has emerged with advances in thermal 
therapy and the relevant instruments. CHPP 
combines the anatomical characteristics of the 
abdominal cavity, the pharmacokinetic 
characteristics of regional chemotherapeutics, 
and the principles of thermal therapy [16,17]. 
High temperatures can kill tumour cells directly 
and promote the diffusion of drugs. The 
synergistic effects of thermal therapy and 
chemotherapy can kill free tumour cells and 
microscopic lesions in the abdominal cavity and 
control ascites. It is much better at controlling 
peritoneal metastasis than other methods. The 
application of CHPP renders uncontrollable, 
recurrent, or locally advanced tumours more 
controllable, without increasing acute or late 
complications [18]. 
 
In this study, the response rate to CHPP for the 
treatment of tumour-induced malignant ascites 
was 85.50 %, which was higher than that of the 
systemic intravenous chemotherapy. The 
improved abdominal distension, reduced ascites, 
and improved KPS score in the test group were 
obviously superior to the changes in the control 
group, which suggests that chemotherapy in 
combination with CHPP is safe and effective for 
the treatment of malignant ascites. The optimal 
temperature for CHPP has not been determined 
and should be the subject of further studies. 
 
Limitations of the study 
 
The survival period and long-term curative 
effects were not investigated because of the 
short follow-up time. Therefore, the number of 
cases should be increased and the follow-up 
time should be extended in future studies to 
clarify the results. In addition, the effects of drug 
concentration and perfusion temperature on 
patients with different constitutions and stages 
may significantly differ. These should be 
individualised to the patient’s condition to reduce 
the incidence of abdominal distension, pain, or 
peritonitis. Moreover, the selection of anti-tumour 
chemotherapeutics should be specific, because 
malignant ascites can be induced by multiple 
tumours and tumours in different sites show 





CHPP can remarkably improve the short-term 
curative effects on malignant ascites and 
enhance the quality of life of patients, without 
increasing toxic and side effects. Thus, it seems 
to be a safe and effective therapeutic approach 
for treating malignant ascites, but further studies 
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